Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

19.95
+0.06000.30%
Post-market: 19.950.00000.00%19:30 EDT
Volume:2.56M
Turnover:51.35M
Market Cap:3.44B
PE:9.09
High:20.24
Open:20.01
Low:19.88
Close:19.89
52wk High:30.96
52wk Low:19.59
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.84
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:2.63
PE(LYR):8.67

Loading ...

Acadia Pharmaceuticals to Join Canaccord Genuity Growth Conference Fireside Chat

Reuters
·
Jul 31

Earning Preview: ACADIA Pharmaceuticals Q2 revenue is expected to increase by 13%, and institutional views are bullish

Earnings Agent
·
Jul 29

How FDA Fast Track For Remlifanserin In Alzheimer’s Psychosis At ACADIA (ACAD) Has Changed Its Investment Story

Simply Wall St.
·
Jul 28

ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
Jul 25

Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Jul 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Jul 22

Acadia Pharmaceuticals is Maintained at Hold by Stifel

Dow Jones
·
Jul 21

Acadia Pharmaceuticals receives FDA Fast Track designation for remlifanserin

TIPRANKS
·
Jul 20

Acadia Pharmaceuticals - Begins Screening and Enrollment for Phase 3 Studies of Remlifanserin

THOMSON REUTERS
·
Jul 20

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

THOMSON REUTERS
·
Jul 20

Acadia Pharmaceuticals - Completes Radiant Phase 2 Enrollment; Topline Results Expected September-october 2026

THOMSON REUTERS
·
Jul 20

Acadia Pharmaceuticals to Report Q2 Results and Host Conference Call

Reuters
·
Jul 16

Bank of America Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Jul 15

H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Jul 09

RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Acadia Pharmaceuticals Names Carl Segerstrom Chief People Officer

Reuters
·
Jul 06

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

THOMSON REUTERS
·
Jul 06

Acadia Pharmaceuticals Principal Accounting Officer James Kihara Sells 11,421 Shares for $297,940.30

Reuters
·
Jun 30

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Insmed (INSM)

TIPRANKS
·
Jun 29

Citi adds ‘upside 90-day catalyst watch’ on Acadia Pharmaceuticals

TIPRANKS
·
Jun 29